Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its practical approach” to drug development ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Currently, the analyst consensus on AbSci is a Strong Buy with an average price target of $7.83, which is a 170.00% upside from current levels. In a report released on January 17, H.C. Wainwright ...

Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in a Vancouver-based AI drug creation company Absci soared on Wednesday after an investment firm Needham ...

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that ...

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...

Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.77 ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. The partnership will leverage AMD Instinct accelerators and ROCm software ...

Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...

Across the recent three months, 7 analysts have shared their insights on Absci (NASDAQ:ABSI), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a ...

Absci (NASDAQ:ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (NASDAQ:AMD) in the AI drug creation company. ABSI is trading +43.97% ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software ...